Jiuwei Cui

Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial

Shun Lü, Qiming Wang, Guojun Zhang et al. · Journal of Thoracic Oncology · 2021 · 143 citations · Full text

Medicine, Oncology, Pharmacology +11

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee et al. · Journal of Clinical Oncology · 2024 · 142 citations · Full text

Medicine, Oncology, Pharmacology +14

Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial

Chang Liu, Zhi Peng, Yanqiao Zhang et al. · The Lancet · 2025 · 105 citations · Full text

Medicine, Oncology, Gastroenterology +8

Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study

Yuankai Shi, Gongyan Chen, Xiang Wang et al. · Journal of Thoracic Oncology · 2022 · 77 citations

Medicine, Neurology, Pharmacology +6

Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer

Naifei Chen, Chengfei Pu, Lingling Zhao et al. · JAMA Oncology · 2024 · 54 citations · Full text

Medicine, Immunology, Oncology +17